Which medications are contraindicated for a child with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications Contraindicated in Children with G6PD Deficiency

Primaquine is absolutely contraindicated in children with G6PD deficiency due to the risk of severe, life-threatening hemolytic anemia 1. Beyond primaquine, only a small number of medications have solid evidence for prohibition in G6PD-deficient children.

High-Risk Medications to Avoid

Based on the strongest available evidence, the following medications should be strictly avoided in children with G6PD deficiency:

Definitively Contraindicated:

  • Primaquine - causes severe hemolysis; G6PD testing must be performed before use 1, 2
  • Dapsone - associated with hemolytic risk 3, 4
  • Rasburicase - high risk for hemolysis 3, 4, 5
  • Methylthioninium chloride (methylene blue) - causes hemolysis 3, 4
  • Nitrofurantoin - documented hemolytic risk 3, 4
  • Phenazopyridine - can trigger hemolysis 3, 4

Important Clinical Considerations

Primaquine-Specific Guidance:

In populations where severe G6PD deficiency is common (notably among Asians with the Mediterranean B- variant), primaquine should not be administered for greater than 5 days as longer periods may result in life-threatening hemolysis 6. The African variant (A-) has milder deficiency and is relatively resistant to severe primaquine-induced hemolysis 7.

Common Pitfalls to Avoid:

Many medications are incorrectly labeled as dangerous for G6PD-deficient patients. A comprehensive evidence-based review found that numerous compounds have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes, not because the drug itself caused hemolysis 3.

Medications That Are Actually SAFE:

Real-world data from over 31,000 G6PD-deficient patients demonstrated safe use of:

  • Nitrofurantoin (prescribed safely to 1,366 patients)
  • Ciprofloxacin and ofloxacin
  • Sulfamethoxazole/cotrimoxazole
  • Sulfasalazine
  • Hydroxychloroquine
  • Phenazopyridine (despite theoretical concerns) 8

Chloroquine is explicitly safe in G6PD-deficient children and can be used for malaria treatment at standard doses 6.

Practical Algorithm for Medication Use:

  1. Before prescribing any antimalarial or oxidative medication: Verify G6PD status through laboratory testing 1

  2. If G6PD deficiency confirmed:

    • Absolutely avoid: primaquine (except ≤5 days in African variant), dapsone, rasburicase, methylene blue, nitrofurantoin, phenazopyridine
    • Safe to use: chloroquine, most antibiotics, most common medications
  3. For malaria treatment in G6PD-deficient children:

    • Use chloroquine as first-line (25 mg/kg total over 3 days) 6
    • Avoid primaquine for radical cure unless African variant AND limited to 5 days maximum
    • Alternative antimalarials (artemisinin combinations, mefloquine) can be used
  4. Monitor for hemolysis signs: jaundice, dark urine, back/abdominal pain, sudden anemia 4

Critical Safety Point:

The majority of hemolytic crises in G6PD-deficient patients are triggered by infections (71.8% in one large study) or fava bean ingestion, NOT medications 8. Only 4.2% of major hemolytic episodes were medication-related in a real-world cohort of nearly 32,000 patients.

Age-specific considerations: Doxycycline is contraindicated in children <8 years (due to dental effects, not G6PD) 1. Mefloquine is not indicated for children <15 kg 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.